Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

IFOSFAMIDE vs IMDEVIMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

IFOSFAMIDE vs IMDEVIMAB: Safety Overview

Metric IFOSFAMIDE IMDEVIMAB
Total FAERS Reports 17,004 432
Deaths Reported 3,365 24
Death Rate 19.8% 5.6%
Hospitalizations 5,230 202
Average Patient Age 36.2 yrs 56.2 yrs
% Female Patients 41.7% 52.7%
FDA Approval Date Apr 4, 2007 N/A
Manufacturer Baxter Healthcare Corporation N/A
Route INTRAVENOUS N/A
Marketing Status Prescription N/A